Is ibrutinib a BTK inhibitor?

Ibrutinib(Ibrutinib) is the first BTKinhibitor approved for marketing, including multiple lymphoproliferative disorders and chronic graft-versus-host disease. Ibrutinib binds to the cysteine u200bu200bresidue produced by the BTK C481S mutation. Ibrutinib is a targeted drug that works by inhibiting Bruton tyrosine kinase (BTK), an enzyme that is part of a key signaling pathway in certain cancers, particularly B-cell leukemias and lymphomas. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.